PAREXEL enhances development network and will provide access to a range of drug development support services, which are customized to meet the needs of Korean national companies and will cover the entire drug development field for its selected investments.
Parexel Consulting and Medical Communications services corporate vice president and worldwide head Ron Kraus said under the leadership of Dongho Lee, the KDDF is expected to be an important resource for emerging biopharmaceutical companies to advance its new technologies.
"This partnership further demonstrates PAREXEL’s continued commitment to the Asia-Pacific region and helps increase our opportunities for industry innovation," Kraus added.
The alliance follows PAREXEL’s 2012 collaborative research agreement with ASAN Medical Center, based in Seoul, Korea.
PAREXEL support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.
KDDF CEO Dong Ho Lee said, "Together with PAREXEL, KDDF will be able to provide professional consulting services to the Korean research communities to advance research activities and promote important innovation."